Elevance Health (ELV) Stock Stays Undervalued Despite Its 37% Run

After a strong 1 year run, Elevance Health now screens as an undervalued stock on several valuation checks, which puts the recent share price strength in a different light for investors trying to judge whether the current level still offers value.

• Elevance Health has returned 37.5% over the past 12 months, which puts fresh attention on whether the recent gains already reflect its fundamentals.
• The appointment of Dr. Patrick Fox to lead Carelon Behavioral Services, alongside expanding use of AI in the business, can support expectations for profitable growth. At the same time, execution risks in scaling behavioral health and technology investments may affect how dependable those expectations prove to be.
• The broader checklist of valuation metrics leans cheap, with Elevance Health earning a high value score of 5 out of 6, which suggests the current market price is on the low side relative to those fundamentals.

The issue now is whether Elevance Health’s recent share price performance has already captured this apparent discount or if there is still room for the valuation to close the gap implied by those checks.

Spot other potential breakouts by comparing Elevance Health with hand picked 52 high quality undervalued stocks that currently screen as inexpensive on fundamentals.

Does Elevance Health Look Undervalued on Earnings?

The P/E ratio is a useful way to see how Elevance Health is priced against its earnings and against other healthcare stocks you could own instead. It gives a quick read on how much investors are currently paying for each dollar of profit.

Elevance Health trades on a P/E of 18.1x, which is below both the wider Healthcare industry average of about 25.3x and a peer group average of 27.8x. A fair P/E based on its profile is estimated at 34.8x, so the current market price implies a sizeable gap to what that framework suggests might be reasonable.

Despite the recent attention around AI driven efficiencies and the appointment of Dr. Patrick Fox at Carelon Behavioral Services, the stock still trades on an earnings multiple that is materially lower than those benchmarks. For investors comparing options within healthcare, Elevance Health’s current P/E points to a weaker valuation than many peers on this measure.

On the P/E multiple, Elevance Health appears undervalued relative to both the modelled fair ratio and the wider healthcare group.

See what the numbers say about this price — find out in our valuation breakdown.

The Elevance Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Elevance Health's valuation puzzle leaves off and explain which earnings, growth and margin paths would need to occur for the stock to be worth materially more or less than it is today. Each narrative links its numbers to a specific view of where Elevance Health's growth, profitability and risks could go next, giving you a reference point you can revisit as new information becomes available.

Community views on Elevance Health are split between a margin recovery story and a slower grind held back by government plan costs.

Bull case: 8% undervalued

"Technology investments in analytics, digitization, and AI are boosting efficiency, reducing costs, and improving margin stability across operations…"

Read the full Bull Case to see why Elevance Health could be undervalued

Bear case: 6% overvalued

"Elevated costs in government-backed plans and greater reliance on value-based care could compress margins despite operational improvements and diversification strategies…"

Read the full Bear Case to see why Elevance Health could be overvalued

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

The Bottom Line

Elevance Health still screens as undervalued on market multiples, even after its strong 1 year return. The key question is whether that discount reflects mispricing or a fair cushion for the execution risks around AI adoption and scaling behavioral health operations. For you as an investor, the central issue is margins. If Elevance Health can keep government plan costs in check while turning technology and Carelon Behavioral Services into steadier profitability, today’s valuation could appear conservative. If those pressures win out instead, the current multiple may prove closer to justified than cheap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com